Staab, Thomas R.; Walter, Miriam; Mariotti Nesurini, Sonja - In: Health Economics Review 8 (2018) 23, pp. 1-11
Background: According to the AMNOG act, the German Federal Joint Committee (G-BA) determines the additional benefit of new medicines as a basis for subsequent price negotiations. Pharmaceutical companies may withdraw their medications from the market at any time during the process. This analysis...
